Hims & Hers Health earnings date
Hims & Hers Health (82W) Q3 2026 Earnings Report
DE:82W Q3 2026 EPS Results
- Actual EPS
- -EUR 0.13
- Consensus EPS
- EUR 0.05
- Beat/Miss
- Missed by -EUR 0.18
- One Year Ago EPS
- EUR 0.05
DE:82W Q3 2026 Revenue Results
- Actual Revenue
- EUR 811.65M
- Expected Revenue
- EUR 814.15M
- Beat/Miss
- Missed by -EUR 2.51M
- YoY Revenue Growth
- +48.65%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/09/2026
- Time
- After Close
- Conference Call
- Monday, November 9, 2026
Hims & Hers Health's next earnings date is estimated for March 1, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was predominantly positive, with strong 49% year-over-year revenue growth, accelerating domestic performance, rapidly expanding international revenue, positive free cash flow, growing adjusted EBITDA, new partnerships and specialty launches, and substantial progress in AI-enabled care. The main negatives were the sequential subscriber decline, $33 million GAAP net loss, 7-percentage-point sequential gross-margin decline, revenue deferrals, lowered adjusted EBITDA guidance, and expected near-term subscriber and margin volatility. Management characterized these pressures as deliberate investments and timing effects while maintaining expectations for positive free cash flow and long-term growth.
Management expects fourth-quarter revenue in the range of $875 million to $895 million, representing a year-over-year increase of approximately 42% to 45%, and adjusted EBITDA to be between $70 million to $90 million, representing an adjusted EBITDA margin of 9% at the midpoint of both ranges; for full year 2026, revenue is expected at $3.13 billion to $3.15 billion, representing a year-over-year increase of 33% to 34%, adjusted EBITDA at $257 million to $277 million, and an adjusted EBITDA margin of 9% at the midpoint of both ranges. Deferred revenue is expected to negatively impact revenue and adjusted EBITDA by at least $20 million for the full year, international revenue is expected to deliver at least $650 million in 2026, and revenue contribution from the peptide offering is not expected to be material in the fourth quarter. Management expects to continue to moderate domestic marketing investment in the U.S. within its weight loss specialty in the fourth quarter, which may lead to an additional quarter of subscriber count headwinds, expects gross margin declines to start to moderate, and expects to drive positive free cash flow for the full year of 2026 and be well-positioned to do the same in 2027; international revenue is on track to eclipse a $1 billion revenue run rate in 2027, while testosterone continues to progress towards achieving a $100 million annualized revenue run rate.
- Accelerating Revenue GrowthThird-quarter revenue grew 49% year-over-year to $890 million, marking the company's second consecutive quarter of accelerating revenue growth.
- Large and Expanding Customer BaseNearly 3 million people across 4 continents rely on Hims & Hers to access care. Subscribers grew 13% year-over-year to 2.8 million.
- Domestic Revenue Growth AcceleratedU.S. operations generated $657 million of revenue in the third quarter, up 21% year-over-year versus 16% growth in the second quarter, despite holding back on marketing investment.
- International Revenue SurgedInternational revenue more than 4x year-over-year to $233 million, including approximately $135 million from Eucalyptus. The remaining international portfolio grew nearly 80% year-over-year.
- International Revenue Outlook IncreasedThe company expects international revenue to be at least $650 million in 2026, up from its prior expectation of $600 million, and said international revenue is on track to eclipse a $1 billion revenue run rate in 2027.
- Expansion of Global Brands and MarketsHers launched in Australia and Germany, expanded its breadth of specialties in the U.K., and Hims launched in Germany and Australia. The company is consolidating brands under Hims & Hers in key markets including the U.K., Germany, and Australia.
- Expanded Weight Loss Partnerships and AssortmentThe company is deepening its partnership with Novo, currently offering the Wegovy Pen and Pill and preparing to add CagriSema once available. Through its agreement with Lilly, Hims & Hers plans to offer customers access to Zepbound and Foundayo across a broader weight loss assortment.
- Weight Loss Platform EnhancementsThe company is preparing flexible multi-month subscriptions, additional pricing options, starter offerings, and broader treatment choices intended to make weight loss treatment more accessible and support customers in starting and staying with treatment.
- AI-Native Experience Reached Most Weight Loss CustomersThe AI-native experience was available to 70% of weight loss subscribers at quarter end, described elsewhere as reaching the large majority of weight loss customers across Hims & Hers. The company expects coverage to reach nearly 100% before year-end and plans to extend the experience to hair, sexual health, and testosterone.
- AI Increased Customer Engagement and Response SpeedCustomers with access to the AI-native experience sent 4x as many messages on the platform. Average response time for non-clinical questions was reduced to minutes rather than hours.
- AI Improved Provider and Operating EfficiencyAI tools generate first drafts of patient responses, help customers complete medical charts, route complicated cases to the appropriate personnel, and reduce non-clinical tasks handled by humans while clinicians remain responsible for clinical decisions.
- Engineering Execution and Hiring MomentumThe quarter was the largest hiring quarter in the history of the engineering organization. Teams are shipping platform updates in under a day, and the number of large-scale project completions more than doubled quarter-over-quarter.
- New Specialty and Controlled-Substance LaunchesThe company expanded testosterone offerings to injectable and oral testosterone replacement therapy, its first controlled-substance launch. Testosterone is progressing toward a $100 million annualized revenue run rate, with the injectable offering launched last month.
- Peptides+ Launch PreparationThe company expects to launch the first phase of Peptides+ later this month, including sermorelin, glutathione, NAD+, and B-12. It plans to add BPC-157 and TB-500 when the regulatory environment permits, supported by its U.S.-based peptide manufacturing and fulfillment facilities.
- Verticalized Infrastructure and Supply ChainHims & Hers owns more than 1 million square feet of pharmacy, laboratory, compounding, and supply-chain infrastructure. The company said this infrastructure supports more complex treatments, domestic manufacturing and compounding, and efficiency gains as more offerings are verticalized.
- Adjusted EBITDA and Cash Flow GenerationAdjusted EBITDA grew 37% quarter-over-quarter to $82 million, representing a 9% adjusted EBITDA margin. Cash flow from operations was $65 million and free cash flow was $26 million in the third quarter.
- Strong Liquidity PositionThe company ended the third quarter with more than $710 million of cash and investments and expects to generate positive free cash flow for the full year of 2026 and again in 2027.
- Operating Cost ImprovementsMarketing as a percentage of revenue improved by 7 percentage points quarter-over-quarter to 28%, operations and support costs improved by 1 percentage point to 12%, and GAAP G&A expenses improved by 5 percentage points to 17%.
- Hers and Specialty ExpansionHers is progressing toward $1 billion of revenue this year, with dermatology and menopause scaling alongside weight loss. The company also plans to expand specialties such as dermatology, sexual health, and low testosterone internationally.
- Evidence of Generic Weight Loss Demand in CanadaIn Canada, where generic weight loss options became available earlier this year, average monthly orders grew more than 50%, while margins benefited from a mix shift toward lower-cost options.
- Wearable Integration StrategyThe company plans to allow universal integration of wearable devices so patients and providers can bring data into the platform. Andrew Dudum also said Hims & Hers may eventually offer its own devices as part of membership at near cost without data-subscription lock-ins.
- Scientific and Clinical Advisory StrengthAndrew Huberman, a neuroscientist and tenured Stanford professor, joined the Board and became a scientific and brand marketing adviser. He is also providing guidance on clinical standards and guardrails for the peptide offering.
DE:82W Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 01, 2027 | 2026 (Q4) | -0.03- | 0.07 | ― | ― |
| Nov 09, 2026 | 2026 (Q3) | 0.05-0.13 | 0.05 | -333.33% (-0.18) | |
| Aug 10, 2026 | 2026 (Q2) | -0.05-0.34 | 0.15 | -317.65% (-0.49) | |
| May 11, 2026 | 2026 (Q1) | 0.02-0.36 | 0.18 | -300.00% (-0.55) | |
| Feb 23, 2026 | 2025 (Q4) | 0.040.07 | 0.1 | -27.27% (-0.03) | |
| Nov 03, 2025 | 2025 (Q3) | 0.090.05 | 0.29 | -81.25% (-0.24) | |
| Aug 04, 2025 | 2025 (Q2) | 0.140.15 | 0.05 | 183.33% (+0.10) | |
| May 05, 2025 | 2025 (Q1) | 0.110.18 | 0.05 | 300.00% (+0.14) | |
| Feb 24, 2025 | 2024 (Q4) | 0.100.10 | 0.01 | 1000.00% (+0.09) | |
| Nov 04, 2024 | 2024 (Q3) | 0.100.29 | -0.04 | 900.00% (+0.33) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


